secwatch.observer — SEC 8-K summary
======================================

Issuer:     Skye Bioscience, Inc. (SKYE)
CIK:        0001516551
Form:       8-K
Filed at:   2023-10-03T23:59:59+00:00
Accession:  0001516551-23-000079
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Skye Bioscience increases authorized common shares from 20M to 100M and expands equity incentive pool
--------------------------------------------------------------------------------

- Board and majority stockholders approved incentive plan amendment raising authorized shares to 1,846,883, with automatic 5% annual increases from 2024-2032.
- Charter amendment increases authorized common stock from 20,000,000 to 100,000,000 shares, approved by majority stockholders via written consent on Sept 29, 2023.
- Both actions become effective 20 calendar days after mailing of definitive information statement to stockholders.
- Incentive plan amendment allows grants of stock options, SARs, restricted stock, RSUs, and performance awards.
- Majority stockholders executed written consents on Sept 29, 2023, bypassing stockholder meeting for both amendments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1516551/000151655123000079/0001516551-23-000079-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1516551/000151655123000079/skye-20230929.htm
  HTML page:      https://secwatch.observer/filing/0001516551-23-000079

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer